Cartesian Therapeutics (RNAC) Earnings Analysis

Cartesian Therapeutics (RNAC) next reports earnings on 2026-08-06, consensus EPS -0.83 USD. Last quarter (2026-04-30) it missed with EPS -1.46 USD vs -0.84 USD est (-73.8%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -1.40.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does RNAC next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.83 USD
Revenue estimate0.00B

RNAC earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-30-1.46 USD-0.84 USD-73.8%Miss
2026-03-09-1.38 USD-0.82 USD-68.3%Miss
2025-11-06-1.38 USD-0.81 USD-70.4%Miss
2025-08-070.5 USD-0.76 USD+165.8%Beat
2025-05-08-0.68 USD-0.61 USD-11.5%Miss
2025-03-20-0.59 USD-0.78 USD+24.4%Beat

Beat rate: 2/6 (33%) over reported quarters with consensus data.

RNAC valuation and analyst view

Trailing P/E-1.40
Trailing EPS-5.65158 USD
Price / book-1.47
Dividend yield0.00%
Market cap0.24B
Analyst consensusBuy (8 buy / 2 hold / 0 sell)
Avg price target25 USD

Related research pages

Frequently asked questions

When is Cartesian Therapeutics (RNAC)'s next earnings date?

Cartesian Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.83 USD and revenue estimate of 0.00B.

Did RNAC beat earnings last quarter?

In its 2026-04-30 report, RNAC posted EPS of -1.46 USD versus a -0.84 USD estimate — a miss of 73.8%.

What is RNAC's earnings track record?

Over the last 6 reported quarters with consensus data, RNAC beat estimates 2 times (33%).

What is RNAC's current P/E ratio and EPS?

RNAC trades at a trailing P/E of -1.40 on trailing EPS of -5.651577250076131 USD.

What do analysts rate RNAC?

Analyst consensus is "Buy" across 10 ratings (0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 25 USD.